BOSTON (Reuters) — Shares of Dendreon (DNDN) tripled Friday after an advisory panel to the U.S. Food and Drug Administration recommended approval of its experimental therapeutic cancer vaccine. Dendreon's Provenge is not a …
There's a common thread through some analysts' notes on biotech stocks this morning: "Here's why this stock isn't like Dendreon (DNDN)." Dendreon helped take down stocks of rival biotech companies today and yesterday after …
NEW YORK (CNNMoney.com) -- Dendreon's stock price surged immediately after the open of Friday trading, following an surprise positive vote from FDA advisors the day before, which favored the experimental prostate cancer treatment …
Yep, we implemented this same trade two years ago prior to the FDA advisory committee meeting that endorsed Provenge, pushing DNDN stock from $4 to $25…a month before it was—shockingly—not approved by the FDA itself, crashing the …
The rights will be exercisable only if a person or group acquires 20 percent or more of Dendreon's common stock or at the times specified in the Rights Plan after a person or group commences or announces a tender offer for 20 percent or …
Dendreon (NASDAQ:DNDN) chief executive John Johnson has talked of the possibility of the company seeking a marketing partner in Europe for its Provenge cancer therapy in an effort to boost sales. Shareholders have been …
Shares of Dendreon are off over 2% today despite an overall flat market. And down 12% in the past week despite the S&P being down about 0.4%. But even more importantly, shares of DNDN, currently at 34 and change are off 23 points from …
Dendreon stock, shown with light-blue shading, dropped more than 70 percent from Tuesday, Aug. 2, to Monday, Aug. 8. The Dow Jones (red), S&P 500 (brown) and Nasdaq (green) are also shown. Dendreon stock, shown with light-blue …
Shares of Dendreon (Nasdaq:DNDN) were gapping down Tuesday morning with an open price 13.6% lower than Monday's closing price. The stock closed at $11.69 yesterday and opened today's trading at $10.10.
NEW YORK (Reuters) - A lightening fast sell-off of shares of biotech company Dendreon last April is drawing scrutiny from U.S. securities regulators and the independent monitor assigned to keep tabs on those regulators, said people …